Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
  • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
  • C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
  • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
  • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
  • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
  • C07C323/40—Y being a hydrogen or a carbon atom
  • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
  • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
  • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
  • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

• This invention relates to new, therapeutically useful benzamide derivatives, to a process for their production and to pharmaceutical compositions
• the new benzamide derivatives of the present invention are the compounds of formula I, hereinafter depicted, wherein R represents a straight- or branched-chain alkyl group containing up to about 20 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups,
• alkoxyalkoxyalkoxyalkyl group optionally carrying one or more substituents selected from halogen, e.g.
• R 6 represents a hydrogen atom or a methyl group and R 7 represents a methyl, trifluoromethyl or trichloromethyl group, the symbols R 2 are the same or different and each represents a hydrogen atom, a straight- or
• R 3 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 6 carbon atoms
• R 4 represents a straight- or
• R 5 represents a group of the formula -NR 8 R 9 or -OR 10 wherein R 8 and R 9 may be the same or different and each represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g.
• R 10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and
• hetero atoms e.g. oxygen, sulphur or nitrogen atoms
• sulphinyl or sulphonyl groups optionally interrupted by one or more sulphinyl or sulphonyl groups, and pharmaceutically acceptable salts thereof .
• R 1 represents an alkyl, alkenyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxyalkoxyalkoxyalkyl or
• haloalkyl e.g. chloroalkyl, group, containing from 8 to 20 carbon atoms, preferably an alkyl or alkenyl group containing from 8 to 20, preferably 10 to 18, carbon atoms;
• R 3 represents a hydrogen atom
• R 4 represents an imidazol-1-yl group or a
• alkoxy or alkylthio group containing up to 3, preferably 1 or 2, carbon atoms, preferably methoxy, methylthio or ethylthio;
• R 8 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 3 carbon atoms, e.g. methyl;
• R 9 represents a straight- or branched-chain
• alkylthioalkyl group containing 3 or 4 carbon atoms or an alkenyl group containing 5 carbon atoms, e.g. a butyl, methoxyethyl,
• R 10 represents a hydrogen atom or a straight- or branched-chain alkyl group containing up to 6, preferably up to 3, carbon atoms, e.g. methyl; the other symbols being as hereinbefore defined, and pharmaceutically acceptable salts thereof.
• Important compounds according to the invention include:- A (Z)-N-(2-methylthio)ethyl-4-methylthio-3- (octadec-9-enamido)benzamide ;
• BC 4-ethylthio-N-(3-methyIthiopropyl)-3-(5,9- dioxaoctadecanamido)benzamide;
• BE 4-ethylthio-N-(3-methyIthiopropyl)-3-(6,10,14- trioxahexadecanamido)benzamide;
• BF 4-imidazol-1-yl-N-(3-methyIthiopropyl)-3-(5- oxahexadecanamido)benzamide;
• the compounds according to the invention are inhibitors of acyl coenzyme-A:cholesterol-O-acyl transferase (ACAT;EC 2.3.1.26). They are therefore of value as anti-atherosclerotic agents and have utility in the treatment of atherosclerosis,
• hyperlipidaemia hyperlipidaemia, cholesterol ester storage disease and atheroma in vein grafts.
• alkoxycarbonyloxy group for example methoxycarbonyloxy or ethoxycarbonyloxy, or with the corresponding
• R 1 and R 2 are as hereinbefore defined.
• the reaction may be performed in the presence of a suitable base, such as a tertiary amine, e.g. triethylamine or
• reaction may be carried out in a suitable solvent, e.g. dichloromethane, optionally with heating.
• a suitable solvent e.g. dichloromethane
• compounds of formula I wherein R is other than hydrogen are prepared by reacting a compound of general formula:
• R 11 represents a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups, or a compound of general formula:
• R 1 , R 2 , R 3 and R 4 are as hereinbefore defined and Z 2 represents a hydroxy group, a halogen, e.g. chlorine, atom or an alkoxycarbonyloxy group, for example
• reaction conditions are similar to those described above for the reaction between the compounds of general formulae II and III.
• reaction is preferably performed in the presence of a condensing agent, such as dicyclohexylcarbodiimide, or a catalytic quantity of an inorganic acid, e.g. hydrochloric acid, optionally prepared in situ.
• a condensing agent such as dicyclohexylcarbodiimide
• a catalytic quantity of an inorganic acid e.g. hydrochloric acid
• reaction may be carried out in a suitable solvent, e.g. dichloromethane, optionally with heating.
• a suitable solvent e.g. dichloromethane
• compounds of general formula I are prepared by the interconversion of other compounds of formula I.
• compounds of general formula I are prepared by the interconversion of other compounds of formula I.
• R 8 and/or R 9 is other than a hydrogen atom are prepared from compounds of formula I wherein R 3 and/or R 8 and/or R 9 represents a hydrogen atom by the application or adaptation of known methods of alkylation; according to a further feature of the invention, (b) compounds of formula I containing a sulphonyl group are prepared by the oxidation of compounds of formula I containing a sulphinyl or thio group and compounds of formula I containing a sulphinyl group are prepared by the
• compounds of formula I wherein R 10 represents a hydrogen atom are prepared from compounds of formula I wherein R 10 represents a straight- or branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g.
• branched-chain alkyl group containing up to about 10 carbon atoms, optionally containing one or more carbon-carbon double or triple bonds, and optionally interrupted by one or more hetero atoms, e.g. oxygen, sulphur or nitrogen atoms, and optionally interrupted by one or more sulphinyl or sulphonyl groups are prepared by the esterification of compounds of formula I wherein R 10 represents a hydrogen atom, by the application or adaptation of known methods.
• pharmaceutically acceptable salts as used in this specification is meant acid addition salts the anions of which are relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial pharmaceutical properties of the compounds of formula I are not vitiated by
• pharmaceuticals may be selected from salts derived from inorganic acids, for example hydrochlorides,
• hydrobromides hydrobromides, phosphates, sulphates and nitrates, and organic acids, for example oxalates, lactates,
• salts of the compounds of formula I are useful for the purposes of purification of the parent compounds, for example by exploitation of the
• the salts can be prepared from the parent compounds of formula I by the application or adaptation of known methods, and the parent compounds of formula I can be prepared from the salts by the application or adaptation of known methods.
• the compounds of formula I can be purified by the usual physical means, for example by
• acid halides of formula VII wherein Z 1 represents a halogen atom may be prepared from the corresponding carboxylic acids of formula VII wherein Z 1 represents a hydroxy group by the application or adaptation of known methods, e.g., when Z 1 represents a chlorine atom, by reaction with thionyl chloride or oxalyl chloride.
• acid halides of formula III wherein Z 1 represents a halogen atom may be prepared from the corresponding carboxylic acids of the general formula:-
• R 1 and R 2 are as hereinbefore defined, by the application or adaptation of known methods, e.g., when
• Z 1 represents a chlorine atom, by reaction with thionyl chloride or oxalyl chloride.
• alkoxyalkyl or, more particularly, an alkoxyalkoxyalkyl or, especially, an alkoxyalkoxyalkoxyalkyl, group, and
• R 2 is as hereinbefore defined, are key intermediates and they, a process for their preparation, and their use in synthesis of useful pharmaceuticals, e.g.
• compounds of formula IX are prepared by the oxidation of compounds of the general formula:-
• R 12 and R 2 are as hereinbefore defined, by the application or adaptation of known methods, for example by reaction with an alkali metal halite such as sodium bromite and a free radical such as 2,2,6,6-tetramethyl- 1-piperidinyloxy free radical.
• an alkali metal halite such as sodium bromite
• a free radical such as 2,2,6,6-tetramethyl- 1-piperidinyloxy free radical.
• This reaction is preferably carried out in the presence of a base such as an aqueous solution of an alkali metal carbonate or bicarbonate, and in the presence of a suitable solvent such as acetonitrile, preferably at or, more especially below room
• a base such as an aqueous solution of an alkali metal carbonate or bicarbonate
• a suitable solvent such as acetonitrile
• aminobenzamide derivative there were prepared:- N-butyl-3-hexadecanamido-4-(methylthio)benzamide, in the form of. white crystals, m.p. 125-126°C [Elemental analysis:- C,70.4;H,10.18;N,5.88;S,6.95%; calculated:- C, 70.54 ; H, 10.15 ; N, 5.88 ; S , 6.73%] ;
• the mixture was stirred at the ambient temperature for 1 hour, then it was diluted with dichloromethane (100ml) and washed sequentially with hydrochloric acid (100ml;1N), aqueous sodium chloride solution (100ml), aqueous potassium hydroxide solution (1.5g in 100ml), hydrochloric acid (100ml;1N) and with aqueous sodium chloride solution (100ml), dried over magnesium sulphate and concentrated under reduced pressure.
• Example 3 sodium hydroxide (0.6g), water (20ml) and ethanol (200ml) was heated at reflux for 1.5 hours.
• the mixture [containing (Z)-sodium 4-methoxy-3-(octadec-9-enamido)benzoate] was cooled to the ambient temperature and was then poured onto a mixture of crushed ice and concentrated hydrochloric acid.
• the product was collected and recrystallised from methanol, to give (Z)-4-methoxy-3-(octadec-9-enamido)benzoic acid (4.14g) in the form of a white powder, m.p.
• N-butyl-3-octadecanamido-4-(methylthio)benzamide in the form of a white powder, m.p. 115-118°C (from a mixture of t-butyl methyl ether and methanol)
• N-butyl-3-(5-chloropentanamido)-4-(ethylthio)benzamide in the form of a white powder, m.p. 104-105°C (from t-butyl methyl ether) [Elemental analysis:- C,58.2;
• N-butyl-4-ethylthio-3-(5,9-dioxahexadecanamido)-benzamide in the form of a pale brown oil (eluting with a mixture of dichloromethane and methanol)
• N-butyl-4-methylthio-3-(5-oxahexadecanamido)benzamide in the form of a pale brown oil that solidified on standing (eluting with a mixture of dichloromethane and methanol) [Elemental analysis:- C,68.0;H,9.9;N,5.6; S,6.24%; calculated:- C, 67.74;H,9.69;N,5.85;S,6.70%]; 4-methoxy-N-(3-methyIthiopropyl)-3-(5,9-dioxahexadecanamido)benzamide, in the form of a pale brown oil (eluting with a mixture of dichloromethane and
• 5-oxahexadecanoic acid in the form of a colourless, mobile oil which solidified, m.p. 28-30°C [Elemental analysis:- C,68.5;H,11.6%; calculated:-C,69.72;H,11.70%].
• Methyl 4-(imidazol-1-yl)-3-nitrobenzoate (19.3g) was reduced by reaction with iron powder (22. Og) in boiling ethanol (150ml) containing water (35ml) and hydrochloric acid (1.5ml;1N). Recrystallisation from ethyl acetate gave methyl 3-amino-4-(imidazol-1-yl)-benzoate (9.7g) in the form of pale yellow crystals, m.p. 161-165°C.
• the present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of formula I, or a
• the compounds of the present invention may be administered parenterally, rectally or orally.
• Solid compositions for oral administration include compressed tablets, pills, powders and
• one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose.
• the compositions may also comprise, as is normal practice,, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
• Liquid compositions for oral administration include pharmaceutically acceptable emulsions,
• compositions according to the invention for oral administration also include capsules of absorbable material such as
• gelatin containing one or more of the active
• Preparations according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions.
• organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
• the compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
• Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formula I.
• compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired
• the doses are generally from about 0.5 to about 70, preferably about 1 to about 10, mg/kg body weight per day by oral administration.
• No. 2 size gelatin capsules each containing:- N-butyl-3-hexadecanamido-4-(methylthio)- benzamide; 20 mg lactose 100 mg starch 60 mg dextrin 40 mg magnesium stearate 1 mg were prepared in accordance with the usual procedure.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10680576

Family Applications (1)

Country Status (10)

Families Citing this family (3)

Family Cites Families (6)

• 1990
  • 1990-08-13 GB GB909017711A patent/GB9017711D0/en active Pending
• 1991
  • 1991-08-12 IE IE284891A patent/IE912848A1/en unknown
  • 1991-08-12 IL IL99159A patent/IL99159A0/xx unknown
  • 1991-08-12 ZA ZA916338A patent/ZA916338B/xx unknown
  • 1991-08-13 EP EP91914392A patent/EP0543865A1/de not_active Withdrawn
  • 1991-08-13 AU AU84275/91A patent/AU8427591A/en not_active Abandoned
  • 1991-08-13 CA CA002089151A patent/CA2089151A1/en not_active Abandoned
  • 1991-08-13 PT PT98666A patent/PT98666A/pt not_active Application Discontinuation
  • 1991-08-13 WO PCT/GB1991/001375 patent/WO1992003412A2/en not_active Application Discontinuation
  • 1991-08-13 JP JP3513671A patent/JPH06500315A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events